•
Jun 30, 2024

STERIS Q1 2025 Earnings Report

Announced financial results for fiscal 2025 first quarter, demonstrating revenue growth and strong segment performance.

Key Takeaways

STERIS reported an 8% increase in total revenue to $1.3 billion and a 6% growth in constant currency organic revenue. As reported EPS increased to $1.41, while adjusted EPS reached $2.03. The company reiterated its fiscal 2025 outlook, expressing confidence in achieving full-year guidance.

Total revenue from continuing operations increased by 8%, with constant currency organic revenue growing by 6%.

As reported EPS from continuing operations increased to $1.41, and adjusted EPS increased to $2.03.

Healthcare revenue grew by 10%, driven by improvements in consumable and service revenue.

Fiscal 2025 outlook has been reiterated, indicating continued confidence in delivering full-year guidance.

Total Revenue
$1.28B
Previous year: $1.29B
-0.4%
EPS
$2.03
Previous year: $2
+1.5%
CC Organic Revenue Growth
6%
Previous year: 11%
-45.5%
Gross Profit
$573M
Previous year: $573M
-0.1%
Cash and Equivalents
$198M
Previous year: $209M
-4.9%
Free Cash Flow
$196M
Previous year: $215M
-8.8%
Total Assets
$10.1B
Previous year: $10.8B
-6.3%

STERIS

STERIS

STERIS Revenue by Segment

Forward Guidance

STERIS continues to expect as reported revenue from continuing operations to increase 6.5-7.5%. Constant currency organic revenue from continuing operations is anticipated to increase 6-7%. Adjusted earnings per diluted share from continuing operations is anticipated to be in the range of $9.05 to $9.25. Capital expenditures are anticipated to be approximately $360 million and free cash flow is expected to be approximately $700 million.

Positive Outlook

  • As reported revenue from continuing operations is expected to increase 6.5-7.5%.
  • Currency is expected to be neutral to revenue in fiscal 2025.
  • Constant currency organic revenue from continuing operations is anticipated to increase 6-7%.
  • Adjusted earnings per diluted share from continuing operations is anticipated to be in the range of $9.05 to $9.25 compared with $8.20 in adjusted earnings from continuing operations in fiscal 2024.
  • Free cash flow is expected to be approximately $700 million.

Challenges Ahead

  • Total annual revenue for the divested business in fiscal 2024 was approximately $35 million which will be excluded from constant currency organic revenue growth from continuing operations in fiscal 2025.
  • Capital expenditures are anticipated to be approximately $360 million.
  • The fiscal 2025 outlook assumes an effective tax rate of approximately 23%.
  • Uncertainties related to tax treatments under the TCJA and the IRA.
  • The possibility that Pillar Two Model Rules could increase tax uncertainty and adversely impact STERIS's provision for income taxes and effective tax rate and subject STERIS to additional income tax in jurisdictions who adopt Pillar Two Model Rules.

Revenue & Expenses

Visualization of income flow from segment revenue to net income